Quantitative brain SPECT in Alzheimer's disease and normal aging
- PMID: 8229257
Quantitative brain SPECT in Alzheimer's disease and normal aging
Abstract
To improve the diagnostic utility of brain single-photon emission computed tomography (SPECT) in Alzheimer's disease (AD), we have developed and evaluated an objective method of differentiating patients and healthy elderly controls using a quantitative image analysis protocol. HMPAO-SPECT image datasets from 29 patients with probable AD and 78 age-matched controls were registered to a common anatomic frame of reference. Activity levels within 120 standardized cortical volumes were determined by an automated procedure. Subjects were classified into normal and AD groups by quadratic discriminant analysis using two features: global average activity level and average normalized activity levels within the two clusters of standardized volumes identified as most significantly different in AD by analysis of covariance. The classification used split-half replication to ensure valid results. Classification performance quantified by the area under a binormal ROC curve fitted to the data was 0.923 +/- 0.036; at a threshold likelihood ratio of 1, the sample sensitivity was 91% and specificity was 86%. We conclude that quantitative SPECT accurately distinguishes AD patients from elderly controls.
Similar articles
-
Comparison of technetium-99m-HMPAO and technetium-99m-ECD cerebral SPECT images in Alzheimer's disease.J Nucl Med. 1996 Nov;37(11):1749-55. J Nucl Med. 1996. PMID: 8917168
-
Abnormalities in rCBF and computed tomography in patients with Alzheimer's disease and in controls.Br J Radiol. 1993 Jan;66(781):23-7. doi: 10.1259/0007-1285-66-781-23. Br J Radiol. 1993. PMID: 8428246
-
High-resolution technetium-99m-HMPAO SPECT in patients with probable Alzheimer's disease: comparison with fluorine-18-FDG PET.J Nucl Med. 1994 Feb;35(2):210-6. J Nucl Med. 1994. PMID: 8294987
-
Sensitivity, specificity, and positive predictive value of technetium 99-HMPAO SPECT in discriminating Alzheimer's disease from other dementias.J Geriatr Psychiatry Neurol. 1997 Jan;10(1):15-21. doi: 10.1177/089198879701000104. J Geriatr Psychiatry Neurol. 1997. PMID: 9100154 Review.
-
The diagnosis of Alzheimer's disease: a question of image?J Clin Psychiatry. 1994 Nov;55 Suppl:22-31. J Clin Psychiatry. 1994. PMID: 7989291 Review.
Cited by
-
Neuroimaging in dementia.Neurotherapeutics. 2011 Jan;8(1):82-92. doi: 10.1007/s13311-010-0012-2. Neurotherapeutics. 2011. PMID: 21274688 Free PMC article. Review.
-
Geraniol attenuates oxidative stress and neuroinflammation-mediated cognitive impairment in D galactose-induced mouse aging model.Aging (Albany NY). 2024 Mar 20;16(6):5000-5026. doi: 10.18632/aging.205677. Epub 2024 Mar 20. Aging (Albany NY). 2024. PMID: 38517361 Free PMC article.
-
Alzheimer's disease and mild cognitive impairment.Neurol Clin. 2007 Aug;25(3):577-609, v. doi: 10.1016/j.ncl.2007.03.008. Neurol Clin. 2007. PMID: 17659182 Free PMC article. Review.
-
The Legacy of the TTASAAN Report-Premature Conclusions and Forgotten Promises: A Review of Policy and Practice Part I.Front Neurol. 2022 Mar 28;12:749579. doi: 10.3389/fneur.2021.749579. eCollection 2021. Front Neurol. 2022. PMID: 35450131 Free PMC article. Review.
-
Neuropsychology of memory and SPECT in the diagnosis and staging of dementia of Alzheimer type.J Neurol. 1996 Feb;243(2):175-90. doi: 10.1007/BF02444012. J Neurol. 1996. PMID: 8750558
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical